Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 22, 2013Journal of Hematology & OncologyOpen Access

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRuben A. MesaUniversity of Insubria
Jorge E. Cortés
Jorge E. CortésAugusta University Health

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mesa et al. (2013) studied this question.

synapsesocial.com/papers/6a096efd59b902245b45c367https://doi.org/10.1186/1756-8722-6-79
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment2008 · 95 citations
  2. 2Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib2012 · 93 citations
  3. 3Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes2013 · 65 citations
  4. 4The evolving treatment paradigm in myelofibrosis2012 · 27 citations
  5. 5Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I2015 · 333 citations